Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, subject to her continued service, giving her 31,250 options beneficially owned after this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reinsdorf Judith A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 31,250 shares Exercise price: $15.86 per share Expiration date: May 14, 2036 +2 more

5 metrics

Option grant size 31,250 shares Director stock option award underlying common stock

Exercise price $15.86 per share Director stock option exercise price

Expiration date May 14, 2036 Option term end date

Vesting deadline May 15, 2027 Latest possible 100% vesting date, subject to service

Post-transaction options held 31,250 options Total derivative securities beneficially owned after grant

Key Terms

Director Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 15.8600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-14T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/15/2026 - 05:53 PM Accepted by SEC EDGAR 05/15/2026 - 05:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reinsdorf Judith A

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		⁽¹⁾	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Judith A. Reinsdorf	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Nurix Therapeutics (NRIX) director Judith Reinsdorf report on this Form 4?

Judith A. Reinsdorf reported receiving a grant of stock options for 31,250 shares of Nurix Therapeutics common stock. These options are a compensation award and do not reflect an open-market purchase or sale of existing shares.

What are the key terms of Judith Reinsdorf’s Nurix (NRIX) stock option grant?

The stock option covers 31,250 shares of Nurix common stock at an exercise price of $15.86 per share. It expires on May 14, 2036, giving a long-dated right to buy shares at that fixed price.

How do the Nurix (NRIX) options granted to Judith Reinsdorf vest?

The option vests 100% on the earlier of the next annual meeting of Nurix stockholders or May 15, 2027. Vesting is conditioned on her continued service to the company through the applicable vesting date.

Did Judith Reinsdorf buy or sell Nurix (NRIX) shares in the open market?

No open-market buy or sell occurred in this filing. The transaction is coded as an “A” grant, reflecting a compensation-related stock option award rather than a purchase or sale on the market.

How many Nurix (NRIX) options does Judith Reinsdorf hold after this transaction?

Following this transaction, she beneficially owns 31,250 stock options tied to Nurix common shares. This equals the full size of the reported grant, as this Form 4 does not list any prior option holdings.

What does the $15.86 exercise price mean for the Nurix (NRIX) option grant?

The $15.86 exercise price is the fixed price at which she may buy Nurix common stock when the option is exercised. If the stock trades above this price after vesting, the option could have intrinsic value.